Clinical efficacy of azacitidine in the treatment of middle- and high-risk myelodysplastic syndrome in middle-aged and elderly patients: A retrospective study.
{"title":"Clinical efficacy of azacitidine in the treatment of middle- and high-risk myelodysplastic syndrome in middle-aged and elderly patients: A retrospective study.","authors":"Liang Li, Jianjun Bian, Yuxuan Su, Chunchun Zhang","doi":"10.1515/med-2025-1151","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to explore the efficacy and safety of azacitidine (AZA) in middle-aged and elderly patients with myelodysplastic syndrome (MDS).</p><p><strong>Methods: </strong>The clinical data of 59 middle-aged and elderly patients with middle- and high-risk MDS, who attended our hospital from April 2019 to January 2024, were retrospectively analyzed and were divided into an observation group (AZA) and a control group (conventional supportive treatment) according to the treatments, and the patients in the two groups were evaluated for their clinical efficacy and safety.</p><p><strong>Results: </strong>The overall response rate of the observation group was 66.67%. In terms of blood cells, the observation group's blood cell level after four courses of treatment was significantly higher than that of the control group (<i>P</i> < 0.05). In terms of lactate dehydrogenase (LDH), the level of LDH decrease after four courses of treatment in the observation group was significantly better than that in the control group (<i>P</i> < 0.05). The safety of both groups was good.</p><p><strong>Conclusions: </strong>AZA is safe and effective in the treatment of high risk MDS in middle and old age patients.</p>","PeriodicalId":19715,"journal":{"name":"Open Medicine","volume":"20 1","pages":"20251151"},"PeriodicalIF":1.6000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11967471/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1515/med-2025-1151","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: The aim of this study was to explore the efficacy and safety of azacitidine (AZA) in middle-aged and elderly patients with myelodysplastic syndrome (MDS).
Methods: The clinical data of 59 middle-aged and elderly patients with middle- and high-risk MDS, who attended our hospital from April 2019 to January 2024, were retrospectively analyzed and were divided into an observation group (AZA) and a control group (conventional supportive treatment) according to the treatments, and the patients in the two groups were evaluated for their clinical efficacy and safety.
Results: The overall response rate of the observation group was 66.67%. In terms of blood cells, the observation group's blood cell level after four courses of treatment was significantly higher than that of the control group (P < 0.05). In terms of lactate dehydrogenase (LDH), the level of LDH decrease after four courses of treatment in the observation group was significantly better than that in the control group (P < 0.05). The safety of both groups was good.
Conclusions: AZA is safe and effective in the treatment of high risk MDS in middle and old age patients.
期刊介绍：
Open Medicine is an open access journal that provides users with free, instant, and continued access to all content worldwide. The primary goal of the journal has always been a focus on maintaining the high quality of its published content. Its mission is to facilitate the exchange of ideas between medical science researchers from different countries. Papers connected to all fields of medicine and public health are welcomed. Open Medicine accepts submissions of research articles, reviews, case reports, letters to editor and book reviews.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
